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Several theories aim to explain the malignant transformation of cells, including the mutation of tumor suppressors and
proto-oncogenes. Deletion of Rb (a tumor suppressor), overexpression of mutated Ras (a proto-oncogene), or both, are
sufficient for in vitro gliomagenesis, and these genetic traits are associated with their proliferative capacity. An emerging
hallmark of cancer is the ability of tumor cells to evade the immune system. Whether specific mutations are related with
this, remains to be analyzed. To address this issue, three transformed glioma cell lines were obtained (Rb−/−, RasV12, and
Rb−/−/RasV12) by in vitro retroviral transformation of astrocytes, as previously reported. In addition, RasV12 and
Rb−/−/RasV12 transformed cells were injected into SCID mice and after tumor growth two stable glioma cell lines were
derived. All these cells were characterized in terms of Rb and Ras gene expression, morphology, proliferative capacity,
expression of MHC I, Rae1δ, and Rae1αβγδε, mult1, H60a, H60b, H60c, as ligands for NK cell receptors, and their
susceptibility to NK cell-mediated cytotoxicity. Our results show that transformation of astrocytes (Rb loss, Ras
overexpression, or both) induced phenotypical and functional changes associated with resistance to NK cell-mediated
cytotoxicity. Moreover, the transfer of cell lines of transformed astrocytes into SCID mice increased resistance to NK
cell-mediated cytotoxicity, thus suggesting that specific changes in a tumor suppressor (Rb) and a proto-oncogene
(Ras) are enough to confer resistance to NK cell-mediated cytotoxicity in glioma cells and therefore provide some
insight into the ability of tumor cells to evade immune responses.
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Varias teorías pretenden explicar la transformación maligna de las células, como es la mutación de genes
supresores de tumor y proto-oncogenes. La deleción de Rb (un supresor de tumor), la sobreexpresión de Ras
mutado (un proto-oncogén), o ambos, son suficientes para desarrollar gliomagénesis in vitro, y estas características
genéticas se asocian con su alta tasa de proliferación. Un rasgo distintivo del cáncer es la capacidad de las células
tumorales para evadir el sistema inmune. Por lo que en este estudio analizamos si las mutaciones específicas están
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relacionadas con la evasión de la respuesta inmune. Para abordar esta cuestión, tres líneas celulares de glioma
transformadas se obtuvieron (Rb−/−, RasV12, y Rb−/−/RasV12) mediante transformación retroviral de astrocitos
in vitro, reportado anteriormente. Además, las células transformadas RasV12 y Rb−/−/RasV12 fueron inyectadas en
ratones SCID y después del crecimiento del tumor se obtuvieron dos líneas celulares de glioma estables. En todas
las células se determinaron la expresión génica Rb y Ras, morfología, capacidad de proliferación, expresión de
MHC I, Rae1δ, and Rae1αβγδε, mult1, H60a, H60b, H60c, como ligandos para receptores de células NK, y su
susceptibilidad a la citotoxicidad mediada por células NK. Nuestros resultados muestran que la transformación de
los astrocitos (pérdida de Rb, la sobreexpresión de Ras, o ambos) indujo cambios fenotípicos y funcionales
asociados con la resistencia a la citotoxicidad mediada por células NK. Además, la transferencia de astrocitos
transformados dentro de ratones SCID aumento la resistencia a la citotoxicidad mediada por células NK, lo que se
sugiere que los cambios específicos en un supresor de tumores (Rb) y un proto-oncogén (Ras) son suficientes
para conferir resistencia a la citotoxicidad mediada por células NK en células de glioma y, por tanto, proporcionar
una idea de la capacidad de las células tumorales para evadir la respuesta inmune.Background
Tumorigenesis is a multiple step process in which genetic
alterations drive the progressive transformation of normal
cells into highly malignant derivatives with well-known
hallmarks [1, 2]. In addition, two “emerging hallmarks” of
cancer have recently been proposed, namely deregulation
of cellular energetics, and avoiding immune destruction [3].
Furthermore, neoplastic transformation drives genome
instability and mutation, and tumor-induced inflamma-
tion [3, 4].
The idea that tumors must escape from immune recogni-
tion implies that tumors can be destroyed by the immune
response [5]. However, some tumors generate an immune
suppressive environment, thus evading immune destruction
[6]. Gliomas are the most common primary tumors in the
brain and are divided into four clinical grades on histo-
pathological and prognosis basis [7]. Several gene expres-
sion alterations and chromosomal abnormalities are
commonly found in gliomas and, in some instances, these
mutations correlate with the clinical grade [8].
In most cancers, the oncogenic Ras is activated, and
20-30 % of all tumors harbor oncogenic point mutations
in Ras. Moreover, if Ras is not mutated, such as in gli-
omas, it is frequently found that the Ras signaling
pathway is disrupted [2].
On the other hand, the tumor suppressor Rb regulates
cell cycle, inhibiting progression into the S phase, by in-
activating the E2F transcription factor, which is critical
for DNA replication. The Cancer Genome Atlas (TCGA)
project has shown that CDKN2A/p16-CDK4/6-RB path-
way is altered in nearly 80 % of primary GBMs with the
most frequent genetic alterations being CDKN2A gene
deletion or mutation, CDK4 amplification, and RB1 mu-
tation or deletion [9, 10].
Natural killer cells (NK) are regarded as the first line of
defense against tumors [11]. Therefore, taking advantage
of an oncogenic Ras expression and Rb inactivation-based
in vitro model of gliomagenesis, as previously reported[12], we explored whether these specific genetic alterations
induce a cell phenotype compatible with glioma cell
evasion from NK cell-mediated cytotoxicity. In addition,
in vitro transformed glioma cells were injected into SCID
mice and after tumor growth, two cell lines that survived
the cytotoxic effect of mice NK cells were also analyzed
and showed increased resistance to NK cell-mediated
cytotoxicity. Together, our results suggest that overexpres-
sion of mutated Ras, down-regulation of Rb, or both gen-
etic traits, confer in vitro resistance to NK cells and that
in vivo NK cell-based selective pressure, selected cells with
an increased in vitro resistance to NK cells.
Results
Characterization of in vitro transformed astrocytes
Four types of transformed astrocytes were obtained,
named as cRbloxP/loxP, RasV12, cRb−/−, and cRb−/−/RasV12.
Overexpression of Ras induced cell morphology hetero-
geneity, including elongated cytoplasm and multinucleated
cells, and loss of contact inhibition, all characteristic traits
of transformed cells. Primary astrocytes (cRbloxP/loxP), and
Rb-deficient astrocytes showed no significant morphologic
alterations. All the four cell types tested positive for glial fi-
brillary acidic protein (GFAP), thus demonstrating their
glial nature.
As expected, the presence of RasV12 was observed in the
cell types in which RasV12 was constitutively activated
(RasV12, and cRb-/ -/RasV12), and the lack of the Rb protein
was observed in the cell types in which Rb gene was re-
moved by the Cre recombinase (cRb−/−, cRb−/−/RasV12).
Likewise, the activation of the DNA damage response, as
assessed by the expression of p53, p-p53, and p-H2AX
was higher in the cRb−/−/RasV12 cells.
No significant cell senescence, as assessed by SA-β-gal
expression was observed in any of the transformed
astrocytes, and the maximal proliferation rate was ob-
served in the cRb−/−/RasV12 cells. All these results,
shown in Fig. 1, were very similar to the reported by
Fig. 1 Characterization of in vitro transformed astrocytes. (a) Morphological changes of astrocytes stained with violet crystal, (b) expression of
GFAP and GFP in transformed astrocytes, by immunofluorescence, (c) expression of pRb, p53, p-p53, RasV12 and p-H2AX, by Western blot with
specific antibodies, (d) cell senescence, as assessed by the percentage of SA-β-galactosidase positive cells, (e) cell proliferation rate, as assessed by
violet crystal violet uptake. All images are representative of at least three independent experiments
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data, the cells that were specifically derived for this work
were characterized.
Rb mutation and overexpression of Ras modify the
expression of ligands for NK cell receptors
To gain some insight into the mechanisms that confer
tumor cells the ability to avoid immune destruction. We
tested the expression of defined ligands for NK cellreceptors, including MHC class I (an NK inhibiting
receptor) and Rae1δ, Rae1αβγδε, mult1, H60a, H60b,
H60c, as well as two molecules involved in programed
cell death (Fas, and FasL); MHC class I, Rae1δ, and
Rae1αβγδε, were analyzed by Western blot, whereas
mult1 and H60a, H60b and H60c expression was ana-
lyzed by real time PCR. Figure 2a shows the normalized
expression of MHC class I (a), Rae1δ (b), Rae1αβγδε (c),
Fas (d), and FasL (e). Ligand expression is presented as
Fig. 2 (See legend on next page.)
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Fig. 2 Ras overexpression and Rb deletion in vitro, induce differential expression of MHC-I, Rae1α, Rae1αβγδε, Fas, FasL, Mult1, H60a, H60b and
H60c. Murine astrocytes were transformed in vitro for the overexpression of Ras, the deletion of Rb or both. In addition, two cell lines were derived
from tumors that develop in SCID mice after transplantation of in vitro transformed astrocytes (T653, and T731). Expression of cell surface
molecules, as indicated, was assessed by flow cytometry after cell staining with specific antibodies, as described in material and methods. Mean
fluorescence intensity numerical values were normalized and given a value of 1.0 for the parental cell (cRbloxP/loxP), and the fold change of
expression for the transformed astrocytes was then calculated. The expression for (a) MHC-1, (b) Rae1, (c) Rae1αβγδε, (d) Fas, and (e) FasL is
shown. Results represent the media +/− S.D. from three independent experiments. mRNA expression for Mult1, H60a, H60b and H60c (f) was
assessed by Real Time PCR using specific primers and SYBR Green dye as described in material and methods. All expression levels of interested
genes were normalized to the housekeeping gene β actin. Gene expression values were then calculated based on the ΔΔCt method. Results
represent the media +/− S.D. from three triplicates. Statistical significance was set at p < 0.05
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formed astrocytes. MHC class I expression was higher in
cRb−/− and lower in Rb−/−/RasV12 astrocytes; Rae1δ ex-
pression was higher in cRb−/−, and lower in Rb−/−/RasV12
astrocytes; Rae1αβγδε expression was higher in cRb−/−,
and lower in Rb−/−/RasV12 astrocytes; FasL expression was
lower in RasV12 astrocytes, and Fas expression was lower
in all transformed astrocytes. Figure 2b shows the mRNA
expression of mult-1, H60a, H60b, and H60c. Mult1 ex-
pression was higher in RasV12 and Rb−/−/RasV12 than in
T731 astrocytes, H60a and H60b expression was higher in
cRbloxP/loxP, cRb−/−, Rb−/−/RasV12 and T731 astrocytes than
in RasV12 astrocytes, H60b expression was higher in
cRbloxP/loxP, cRb−/−, Rb−/−/RasV12 and T731 astrocytes than
in RasV12 astrocytes, and H60c expression was higher in
RasV12, Rb−/−/RasV12, T651 and T731 than in cRbloxP/loxP
and cRb−/−astrocytes.
Rb mutation and overexpression of Ras induces
resistance to NK cell mediated cytotoxicity
Transformed astrocytes were exposed to murine NK
cells in order to assess their susceptibility to NK cell-
mediated cytotoxicity. Figure 3 shows that in an effector
to target ratio of 10:1, approximately 30 % of untrans-
formed astrocytes were lysed by NK cells, whereas allFig. 3 Ras overexpression and Rb deletion induce resistance to NK cell-me
purified from C57 mice spleens and co-cultured with in vitro transformed a
4 h of incubation at 37 °C, cells were stained with 7-AAD and the percenta
and referred to as the % of NK cell-mediated cytotoxicity. Results show the
NK cell-mediated cytotoxicity was lower in transformed cells than in the patransformed astrocytes tested were more resistant to NK
cell-mediated cytotoxicity, as shown by the reduced per-
centages of specific lysis.
RasV12 and cRb−/−/RasV12 astrocytes produce tumors in
FVB immunocompetent mice
To assess the capacity of transformed glioma cell lines
to produce tumors in syngeneic immunocompetent
mice, we injected 1x106 cells from either cRbloxP/loxP,
RasV12, cRb-/ -, or cRb−/−/RasV12 astrocytes in FVB mice
(10 animals per group). As shown in Fig. 4, only RasV12
and cRb−/−/RasV12 astrocytes formed tumors. Tumors
formed by injection with RasV12 cells grew during the
first week, and after that, all the tumors formed were
reabsorbed. cRb−/−/RasV12 tumors grew during the first
two weeks and then began to involute until the fourth
week. At about this time, tumors were completely
reabsorbed.
Effect of Rb deleted and/or RASV12 overexpressed tumor
cells on immune cell phenotype in the peripheral blood
In order to analyze the immune response against trans-
formed glioma cell lines with Rb deletion and/or RASV12
overexpression in an homologous syngeneic model of
tumor transplantation, the percentages of differentdiated cytotoxicity in in vitro transformed astrocytes. NK cells were
strocytes (GFP expressing cells) to an effector target ratio of 10:1. After
ge of dead cells in the GFP+ population (target cells) was calculated,
media +/− S.D. of four independent experiments. In all cases the % of
rental (cRbloxP/loxP) cells (p < 0.001)
Fig. 4 Ras overexpression and Rb deletion in vivo produce tumours
in a syngeneic model. 1x106 cRbloxP/loxP, RasV12, cRb−/−, or cRb−/−/RasV12
transformed astrocytes were subcutaneously injected in FVB
immunocompetent mice. Tumours were measured weekly and their
volumes (in cubic millimeters) were reported in the graph during
28 days post-implant. Results show the media +/− S.D. of 10 mice
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ipheral blood of mice in which tumor cells had been
injected 28 days earlier. Figure 5 shows that mice
injected with the cRb−/−/RasV12 astrocytes increase the
percentage of cytotoxic CD8+ lymphocytes, as compared
to the other groups of mice (p = 0.026); a significant re-
duction in the percentage of regulatory CD4 + CD25+
lymphocytes was observed in mice injected with RasV12
or cRb−/− (p = 0.001). In addition, the group implanted
with RasV12 cells developed a significant increment in
the percentage of activated T cells, both CD4 + CD69+
and CD8 + CD69+ cells (p = 0.016 and p = 0.001 respect-
ively). In all groups of transformed glioma cell line-
injected mice, the percentage of granzyme-expressing
cells increased as compared to the mice injected with
cRbloxP/loxP astrocytes.Discussion
The immune system is thought to be constantly survey-
ing for the arising of malignant cells that would in turn
be eliminated by the immune response [13]. An “emer-
ging hallmark” of cancer states that tumor cells are
capable of avoiding immune destruction [3].
In gliomas from human origin, the formed tumor is
immunosuppressive [14, 15]. How these tumors reach
that immunosuppressive characteristic at the early stages
of malignant transformation, and whether specific muta-
tions are associated with the ability to escape from the
immune response is poorly understood. Here, by using a
previously reported in vitro model of gliomagenesis [12],
we tested the hypothesis that defined changes in theexpression of a proto-oncogene (Ras) and a tumor sup-
pressor (Rb) confer tumor cells the ability to avoid im-
mune destruction. In particular, we addressed the
resistance to NK cell-mediated cytotoxicity. Since NK-
cell mediated cytotoxicity is dependent on the tumor
cell membrane expression of several ligands that upon
engagement with specific NK cell receptors either in-
hibit or activate NK cell cytotoxic function, the expres-
sion of MHC class I (ligand for inhibiting NK receptor
Ly49D), Rae1δ, Rae1αβδγε, mult1, H60a, H60b, and
H60c (ligands for NKG2D, an activating NK cell recep-
tor) [16–19], as well as of Fas and FasL (molecules in-
volved in programed cell death) was assessed in vitro
transformed astrocytes. In gliomas from human origin,
deregulated expression of MHC-I has been associated
with NK cell-mediated cytotoxicity [20], and stem cells
from glioma patients do not express protective levels of
MHC-I molecules, but they express several ligands that
activate NK cells [21].
These studies assessed the susceptibility of both stem
cells and tumor cells to NK cell-mediated cytotoxicity,
after the onset of malignant transformation and there-
fore after immunoediting had likely already taken place
[5, 22]. Although, down-regulation of MHC-I makes
tumor cells susceptible to NK cell-mediated cytotoxicity
[22], high expression of MHC-I does not necessarily
guarantee resistance to NK cells [23]. Here, we assessed
the expression of MHC-I on various in vitro transformed
astrocytes that therefore were not subjected to any
immune-based selective pressure. Results showed a signifi-
cant increase in the expression of MHC-I in the cRb−/−
cells and a significant decrease in the cRb−/−/RasV12 cells
(Fig. 1a). When Rb−/−/RasV12 cells were inoculated into
SCID mice, and the T731 tumor cell line was derived, the
expression of MHC-I was similar to that of cRbloxP/loxP
cells (Fig. 1a). This MHC-I expression recovery may be
the result of selective pressure exerted by NK cells in the
SCID mice that selected cells with the highest levels of
MHC-I, conferring them an advantage to evade the NK
cell anti-tumor response. In this regard, the T731 cell line
also showed the lowest percentage of NK cell-mediated
cytotoxicity (Fig. 2). However, the lower expression of
MHC-1 observed in Rb−/−/RasV12 cells, and the higher ex-
pression of Rae1α and Rae 1αβγδε observed in cRb−/− cells
seem to be in contradiction with their increased resistance
to NK cells. Rae1 expression is low or absent in normal
tissues and it is constitutively expressed on some tumor
cells. Upon engagement with the NKG2D receptor on
NK cells, it activates their cytotoxic activity [24, 25].
Rae1 expression has been associated with cell prolifera-
tion [26], and Rae1 gene family members are activated
by the E2F transcription factor, which plays a central
role in regulating cell cycle entry [27]. A significant in-
crease in the expression of Rae1δ and Rae1αβγδε was
Fig. 5 Flow cytometry analysis of peripheral blood. (a) % of T helper lymphocytes (CD4+) from mice implanted with transformed astrocytes, (b) % of T
cytotoxic lymphocytes (CD8+) from mice implanted with transformed astrocytes, (c) % of late activate T helper lymphocytes (CD4+/CD25+) from mice
implanted with transformed astrocytes, (d) % of early activated T cytotoxic lymphocytes (CD8+/CD69+) from mice implanted with transformed
astrocytes, (e) % of early activated T helper lymphocytes (CD4+) from mice implanted with transformed astrocytes, (f) % of macrophages (CD68+) from
mice implanted with transformed astrocytes, (g) % of cells containing granzyme from mice implanted with transformed astrocytes. Results show the
media +/− S.D. of 10 mice
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parental cRbloxP/loxP astrocytes (Fig. 2b and c). Ras in-
duces the expression of Rae1 [28]. However, in this
case, overexpression of Ras (RasV12 astrocytes) did notcorrelate with an increase in Rae1δ or Rae1 αβγδε
expression. Moreover, in cRb−/−/RasV12 astrocytes a sig-
nificant reduction in the expression of both Rae1δ, and
Rae1αβγδε was observed (Fig. 1). The T653 and T731
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Rae1δ, or Rae1αβγδε expression, as compared with
parental cRbloxP/loxP astrocytes. This would suggest that
loss of Rb promotes the expression of Rae1δ, and
Rae1αβγδε. However, since these two ligands would
engage with the NK cell activating NKG2D receptor,
increased NK cell-mediated cytotoxicity against cRb−/−
astrocytes, as compared to that of cRbloxP/loxP astrocytes
would be expected. This was clearly not the case, since
the percentage of NK cell-mediated cytotoxicity was in
fact lower than that for cRbloxP/loxP astrocytes (Fig. 3).
The mRNA expression of four other ligands for
NKG2D cell receptors was also assessed (mult1, H60a,
H60b, and H60c). These ligands are poorly expressed
on most normal cells, but are upregulated on tumor
cells, which is keeping with the finding that mult1
mRNA expression was comparatively higher in RasV12
and cRb−/−/ RasV12 cells than in cRbloxP/loxP cells. On
the other hand, the mRNA expression of mult1 was
similar between cRbloxP/loxP and cRb−/− cells, thus sug-
gesting that transformation due to RasV12 over expres-
sion but not to Rb deletion would render transformed
astrocytes more susceptible to NK cytotoxicity. Again,
this was not the case, since both RasV12 and cRb−/−/
RasV12 astrocytes were more resistant to NK cytotox-
icity. However, in analyzing the mRNA expression of
H60a and H60b, results evident that their expression is
lower in RasV12 and cRb−/−, as compared to cRbloxP/loxP
astrocytes. In addition, mRNA expression of H60a and
H60b is similar in cRb−/−/ RasV12 and cRbloxP/loxP as-
trocytes. Therefore H60a and H60b expression would
imply resistance to NK cell cytotoxicity, as it actually
happens.
The molecule Fas induces cell death upon engagement
with FasL (Fas ligand) [29]. FasL is expressed on acti-
vated T and NK cells [30] and thus FasL induces apop-
totic cell death on Fas-expressing cells [28]. Accordingly,
a decrease in Fas expression would protect cells from
cell-mediated cytotoxicity. The loss of Fas expression
has been observed in melanoma, breast cancer,
leukemia, and lymphoma cells [31–33]. A variety of ma-
lignant tumors show increased expression of FasL, thus
allowing tumor cells to induce apoptosis on cytotoxic
cells, in a process known as “tumor counterattack” [34–
36]. Here we showed that overexpression of Ras, dele-
tion of Rb, or both, are sufficient to decrease the expres-
sion of Fas (Fig. 1d). Lower expression of Fas was
concomitant to increased resistance to NK cell-mediated
cytotoxicity (Fig. 2). No significant increase in the ex-
pression of FasL was observed in any of the transformed
astrocytes. The FasL expression data suggest that genetic
alterations other than just Ras overexpression and Rb
deletion are required for the “tumor counterattack”
phenotype acquisition. It is tempting to speculate thatthis phenotype only takes place after acquisition of
resistance to NK cells and further genome instability, a
property of neoplastic transformation [3].
Additional experiments were designed to evaluate the
tumor growth in a syngeneic model (FVB mice) and the
possible contribution of other immune cells in the
tumor implantation outcome. cRb−/−/RasV12, followed by
cRb−/− astrocytes were successfully implanted. This
could be explained in part by the mRNA expression of
H60a and H60b, as mentioned before, and the conse-
quent resistance to NK cell-mediated cytotoxicity (Fig. 3).
However, the expression of other ligands for NKG2D is
contradictory, mult1 for instance. If tumor implantation
can be attributed to resistance to NK cell cytotoxicity,
tumor remission could then be attributed to the increase
in the percentages of CD8+ and granzyme+ cells in the
case of cRb−/−/RasV12 tumor, and to the increase in the
percentages of CD8+CD69+, CD4+CD69+ and granzyme+
cells, and to the decrease in the percentage of regulatory
CD4+CD25+ cells in the case of RasV12 tumor. It is
worth noting that the most resistant tumor is the one
with the two mutations and also the one that after
28 days post implantation only induced an increase in
the percentage of CD8+ and granzyme+ cells as com-
pared with the RasV12 that induces phenotype changes
more consistent with anti-tumor immunity.
Taken together, our results suggest that Ras overex-
pression and Rb deletion are sufficient for the malignant
transformation of astrocytes and that these genetic alter-
ations confer transformed cells resistance to NK cell-
mediated cytotoxicity, by altering the expression of NK
cell receptor ligands, such as the higher expression of
MHC-I observed in cRb−/− cells, or the lower expression
of Rae1α and Rae1αβγδε observed in Rb−/−/RasV12 cells,
and also by altering the expression of cell death associ-
ated molecules such as Fas, as observed in RasV12 cells.
Its seems that the innate immune system deals with
small antigenic differences between the normal and
transformed tumor cells that allow tumor cells to initiate
proliferation and to develop a number of oncogenic
stages, however further analyses will be required.
Methods
Cell culture and cell proliferation assays
Astrocytes were isolated from 3 days old Rb floxed mice,
as previously described [12]. Animal care and use of all
experimental animals were performed in accordance
with institutional ethical guidelines. In order to intro-
duce an active Ras allele or to promote the Rb loss in as-
trocytes, Phoenix-Eco packaging cells (a kind gift from
G.P. Nolan) were transfected with empty pBABE,
pBABE-HRasV12, empty PIG, and PIG-CRE retroviral
plasmids (a kind gift from P.P. Pandolfi), and in vitro
transformation was achieved by retroviral infection. The
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cRb−/−, and cRb−/−/RasV12. The T653 and T731 cell lines
were derived from tumors formed by inoculation of
Rasv12 and cRb−/−/RasV12 cells in SCID mice, as previ-
ously shown [12]. A feature of the SCID mice is a defi-
ciency in the recombination of genes needed for full
maturation of T and lymphocytes. However, SCID mice
harbor functional NK cells. Cells were maintained in
Dulbecco Modified Eagle Medium (DMEM) (Sigma-
Aldrich, St Louis, MO) supplemented with 10 % FBS
and antibiotic-antimycotic solution (Bio West, Nuaillé,
France). For cell growth analysis, 5x103 cells were plated
into 24-well culture plates (Corning, NY, USA) and then
fixed with methanol/acetic acid (3:1) on days 1, 3, 5, 7 of
culture, for subsequent staining with crystal violet (0.1 % in
PBS) and distaining with 10 % acetic acid. The relative cell
number was assessed by spectrophotometry.
Syngeneic model
The performance of tumor growth in the syngeneic
model was evaluated by subcutaneously injecting 1x106
cRbloxP/loxP, RasV12, cRb−/−, or cRb−/−/RasV12 astrocytes
previously obtained from FVB mice (n = 10). Tumours
from all animals (10 per group) were measured weekly,
and their volumes (in cubic millimeters) were deter-
mined with the formula 6/π × L × W × H. After 28 days,
animals from all groups were anaesthetized and sacri-
ficed by exsanguination.
Flow Cytometry of T lymphocytes, macrophages and
granzyme
Immunofluorescence using monoclonal antibodies was
used to determine the percentages of CD68+, CD4+,
CD8+, CD4+/CD25+, CD8/CD25+, CD8+/CD69+, CD4
+/CD69+ and granzyme+ cells in the peripheral blood
samples, (Biolegend, USA). Briefly, 30 μl of blood were
incubated for 30 min with 5 μl of the corresponding
monoclonal antibody (1:100 dilution) afterwards, 200 μl
of lysis solution were added (Becton Dickinson, Califor-
nia), incubated in darkness for 10 min and washed twice
with 0.1 M PBS (pH 7.2), 0.1 % BSA and 0.1 % NaN3.
The cells were then fixed in 1 % paraformaldehyde solu-
tion and stored at 4 °C until examination by flow cytom-
etry (FACSCalibur, Becton Dickinson) using the Cell
Quest software. 10,000 events in the region correspond-
ing to lymphocytes were analyzed. From this region, the
percentage of positive cells from each sample was deter-
mined. Results were expressed as means (±SD) for each
experimental group.
Senescence assay
Cell senescence was assessed by the expression of β-
galactosidase, by using a β-galactosidase staining kit
(Cell Signaling, Danvers, MA). Cells (5x103) were platedin triplicate into 24-well culture plates (Corning, NY,
USA) and then fixed on day 6 of culture for subsequent
β-galactosidase staining.
Immunoblot
Cell proteins were extracted in RIPA buffer (1 % Nonidet
P-40, 0.5 % sodium deoxycholate, 0.1 % SDS in PBS) in
the presence of 40 μg/ml of aprotinin, 10 μg/ml PMSF
and 100 mM orthovanadate. 40 μg of total protein were
separated by 8 % or 12 % SDS-PAGE and transferred to
nitrocellulose membranes. Western blot were developed
with antibodies against p-p53 (Cell signaling, Danvers,
MA), p-H2AX (Millipore, MA, USA), p53 (cell signaling,
Danvers, MA), pan-Ras-V12 (Calbiochem, MA, USA), p-
Rb (BD Biosciences, San Jose, CA, USA), or α-tubulin
(Sigma-Aldrich, St Louis, MO).
Phenotypic analysis (by Immunofluorescence)
Cells were growth in 8-well polystyrene chambers (BD
Falcon, San Jose, CA, USA) until 80 % confluence, fixed
with 4 % paraformaldehyde in PBS, blocked with 1 %
BSA in PBS, and labeled overnight at 4 °C with anti-
GFAP antibody (Millipore, MA, USA) followed by Alexa
fluor-594-conjugated anti-rabbit IgG (Invitrogen). Cells
were mounted in Vectashield (Vector, CA, USA) and an-
alyzed by confocal microscopy (LSMS Pascal, Zeiss).
Phenotypic analysis (by Flow cytometry)
Cells were suspended in blocking buffer (0.5 % BSA/
2 mM EDTA, in PBS) and then labeled with
fluorochrome-conjugated antibodies: PE-conjugated
anti-Fas (BD Biosciences, San Jose, CA, USA), PE-
conjugated anti-FasL (Biolegend, San Diego, CA) (1 μg/
ml), or anti-MHC-I (Biolegend, San Diego, CA), anti-
RAE-1δ (Biolegend, San Diego, CA), anti-Rae-1αβγδε
(scbt, CA, USA) (1:50), followed by APC-conjugated
anti-mouse IgG (scbt, CA, USA) or APC-conjugated
anti-rabbit IgG (scbt, CA, USA) (1:50) secondary anti-
bodies, as appropriate. Cell membrane expression of
these molecules was assessed by Flow Cytometry (FACS
Aria III, BD Biosciences). Raw data was further analyzed
by using Flow Jo software (Tree Star, Inc. Ashland OR).
NK cytotoxicity assays
NK cells were purified from mice spleens (C57 strain),
hosted in the INNN animal house, in accordance with
institutional guidelines, by using the NK cell isolation kit
II (Myltenyi Biotech, Germany), following the manufac-
turer”s instructions. NK cell cytotoxicity against tumor
cells was evaluated by using Lecoeur et al. method [37].
Since the tumor cells here used express green fluores-
cent protein (GFP) due to the transformation procedure,
there was no need to label them. Isolated NK cells and
tumor cells were co-cultured in 10 % FBS/DMEM at
Orozco-Morales et al. Cancer Cell International  (2015) 15:57 Page10of111:10 target/effector cell ratio, for 4 h. After which, cells
were labeled for 15 min with 7-aminoactinomycin D
(BD Pharmingen, San Jose, CA, USA) at a final concen-
tration of 20 μl/ml. Flow cytometry analysis was used to
calculate the percentage of green fluorescent cells
(tumor cells) that were stained by 7-AAD (dead cells).
Results are expressed as the percentage of specific lysis
calculated by the following formula:
% specific lysis ¼ 100  % sample lysis − % basal lysisð Þ=
100 − % basal lysis
Quantitative polymerase chain reaction
Total RNA was extracted via the phenol/chloroform
method using TRIzol reagent (Invitrogen). Quantitative
polymerase chain reaction (PCR) was performed using EX-
PRESS One-Step SYBR® GreenER™ Kit (Invitrogen, USA).
Emissions from the SYBR Green reporter dye were moni-
tored with an ABI Prism 7500 Real Time PCR (Applied





tisense); H60b, 5′-AGCCTTTTGGTCCTGCTGAAT-3′ (se
nse), H60b, 5′-ATGTTTTTTATCACCAAAATCAAGGAG
T-3′ (antisense); H60c, 5′-CTTCTCTTGATCCTGGAGTC
CTGTAGT-3′ (sense), H60c, 5′-GAGAGTCTTTCCATTC
ACTGAGCAC-3′ (antisense); β-actin, 5′-TTCTACAATGA
GCTGCGT-3′ (sense), β-actin, 5′-ATCACAATGCCTGTG
GTA-3′ (antisense). All expression levels of interested genes
were normalized to the housekeeping gene β-actin. Gene
expression values were then calculated based on the ΔΔCt
method.
Statistical analyses
Data was summarized as arithmetic means and standard
deviations (SD). One-way analysis of variance (ANOVA)
and post-hoc (Tukey) test were conducted. Statistical sig-
nificance was set at p < 0.05 in a two-sided test. SPSS soft-
ware package V 18.0 for Windows; (SPSS Inc., Chicago,
IL) was employed for data analysis.
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